IL210717A - Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection - Google Patents

Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection

Info

Publication number
IL210717A
IL210717A IL210717A IL21071711A IL210717A IL 210717 A IL210717 A IL 210717A IL 210717 A IL210717 A IL 210717A IL 21071711 A IL21071711 A IL 21071711A IL 210717 A IL210717 A IL 210717A
Authority
IL
Israel
Prior art keywords
infections
antibody
composition
dengue
inhibiting
Prior art date
Application number
IL210717A
Other languages
English (en)
Hebrew (he)
Other versions
IL210717A0 (en
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of IL210717A0 publication Critical patent/IL210717A0/en
Publication of IL210717A publication Critical patent/IL210717A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL210717A 2008-07-18 2011-01-18 Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection IL210717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18
PCT/US2009/050966 WO2010009380A2 (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Publications (2)

Publication Number Publication Date
IL210717A0 IL210717A0 (en) 2011-03-31
IL210717A true IL210717A (en) 2017-07-31

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210717A IL210717A (en) 2008-07-18 2011-01-18 Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection

Country Status (13)

Country Link
US (1) US8815813B2 (enExample)
EP (1) EP2320924B1 (enExample)
JP (1) JP5806112B2 (enExample)
CN (1) CN102159231B (enExample)
AU (2) AU2009270805B2 (enExample)
BR (1) BRPI0915968B1 (enExample)
CA (1) CA2731218A1 (enExample)
HR (1) HRP20150620T1 (enExample)
IL (1) IL210717A (enExample)
MX (1) MX2011000647A (enExample)
MY (1) MY160699A (enExample)
SG (1) SG10201500597YA (enExample)
WO (1) WO2010009380A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005221187B2 (en) 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
CN102159231B (zh) 2008-07-18 2016-06-15 三一治疗公司 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法
US20170360875A1 (en) * 2014-12-22 2017-12-21 Middle Tennessee State University Methods for treating immune-mediated viral infections
JP6872181B2 (ja) * 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
CN1189166C (zh) 1998-09-11 2005-02-16 伊来克萨斯独资有限公司 Fc受体调节剂及其应用
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1332158B1 (de) 2000-11-08 2007-08-01 Fresenius Medical Care Affina GmbH Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
DE60318065T2 (de) 2002-06-07 2008-11-20 Trillium Therapeutics Inc., Toronto Fcyriia-transgenes tiermodell für autoimmunkrankheit
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
AU2005221187B2 (en) * 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
AU2005272598B2 (en) 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US20080187490A1 (en) 2005-09-06 2008-08-07 Bodie Neil M Methods for Treating Amyotrophic Lateral Sclerosis
ES2359218T3 (es) 2005-12-13 2011-05-19 Suppremol Gmbh POLIPÉPTIDOS Y POLIMÉRICOS PARA LOS RECEPTORES Fc.
US20120021988A1 (en) 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
CN102159231B (zh) 2008-07-18 2016-06-15 三一治疗公司 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法

Also Published As

Publication number Publication date
IL210717A0 (en) 2011-03-31
CN102159231A (zh) 2011-08-17
US8815813B2 (en) 2014-08-26
BRPI0915968B1 (pt) 2021-11-23
WO2010009380A9 (en) 2010-04-08
JP2011528665A (ja) 2011-11-24
HRP20150620T1 (xx) 2015-09-25
HK1158066A1 (en) 2012-07-13
JP5806112B2 (ja) 2015-11-10
US20110218157A1 (en) 2011-09-08
SG10201500597YA (en) 2015-04-29
EP2320924A4 (en) 2012-07-25
WO2010009380A2 (en) 2010-01-21
MX2011000647A (es) 2011-09-29
CA2731218A1 (en) 2010-01-21
AU2017200760A1 (en) 2017-03-02
EP2320924B1 (en) 2015-03-11
MY160699A (en) 2017-03-15
EP2320924A1 (en) 2011-05-18
AU2009270805B2 (en) 2016-11-03
CN102159231B (zh) 2016-06-15
BRPI0915968A2 (pt) 2020-08-18
AU2009270805A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
GB2471806B (en) Compositions and methods for treating viral infections
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
ZA201109187B (en) Treatment and prevention of dengue virus infections
IL202573A0 (en) Methods and compositions for treating allergic diseases
IL210319A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
EP2236557A4 (en) HYDROPHILIC COMPOSITION WITH MOLD-RESISTANT EFFECT AND HYDROPHILIC ELEMENT
IL195272A0 (en) Methods and compositions for the treatment of viral infections
PT2291654T (pt) Preparação e composição de proteínas inibidoras de interalfa do sangue
PL2252671T3 (pl) Podobna do azeotropu kompozycja 1,1,1-trifluoro-3-chloropropenu i dimetoksymetanu
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2331123A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
IL208403A0 (en) Compositions and use of epas1 inhibitors
PL2252669T3 (pl) Kompozycja typu azeotropu 1,1,1-trifluoro-3-chloropropenu (HCFO-1233zd) i octanu metylu
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
ZA201007091B (en) Vaccine compositions for the treatment of dengue fever and uses thereof
ZA201002181B (en) Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
EP2322175A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
IL178495A0 (en) Composition comprising crustacean gastrolith components and its use
IL210717A0 (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
ZA201002182B (en) Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
EP2329820A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND METABOLIC SYNDROME AND THEIR USE
GB0601950D0 (en) Compositions and methods of treating diabetes
GB2461611B (en) Composition and use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed